UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000009886
Receipt No. R000011539
Scientific Title Study on the clinical efficacy of Eribulin as the first- or second-line treatment in patients with recurrent HER2- negative breast cancer (randomized Phase II study)(JBCRG-19)
Date of disclosure of the study information 2013/02/01
Last modified on 2019/09/05 14:56:26

No. Disposal Last modified on Item of update
1 Insert 2013/01/28 16:22:10
2 Update 2013/06/14 16:27:45 Recruitment status
3 Update 2013/07/29 10:48:02 Institutions
4 Update 2013/12/06 13:50:11 Email
5 Update 2013/12/06 14:01:48 Public title
Public title
6 Update 2013/12/06 14:18:43 Condition
Condition
Narrative objectives1
Narrative objectives1
Key secondary outcomes
Key secondary outcomes
7 Update 2013/12/06 15:03:37 Key inclusion criteria
Key inclusion criteria
8 Update 2014/07/29 09:50:06 Interventions/Control_2
9 Update 2014/07/29 09:55:35 Address
Address
TEL
Address
Address
TEL
Institutions
10 Update 2014/07/29 09:57:20 Last follow-up date
11 Update 2014/09/10 14:14:40 Public title
12 Update 2014/09/10 14:16:26 Public title
13 Update 2014/09/10 14:18:19 Condition
Narrative objectives1
14 Update 2014/09/10 14:30:14 Key inclusion criteria
Target sample size
15 Update 2014/09/10 14:31:00 Last follow-up date
16 Update 2014/09/17 10:22:30 Public title
17 Update 2014/09/17 10:23:21 Condition
Narrative objectives1
18 Update 2014/09/17 10:39:18 Key inclusion criteria
19 Update 2015/07/28 10:50:34 Institutions
20 Update 2016/02/02 14:06:39 Last follow-up date
21 Update 2016/07/08 15:39:17 Recruitment status
22 Update 2016/07/08 15:40:05 Name of primary sponsor
Organization
23 Update 2018/02/01 09:09:49 Recruitment status
24 Update 2018/08/23 15:15:16 Recruitment status
Last follow-up date
25 Update 2018/08/24 10:07:56 UMIN ID1
26 Update 2019/03/28 16:21:14 Recruitment status
Date of IRB
Anticipated trial start date
Last follow-up date
27 Update 2019/09/05 14:53:49 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address
Address
Email

Last name of contact person

Last name of contact person
Zip code
Address
Address
Organization
Organization
Address
Address
Tel
Email
28 Update 2019/09/05 14:56:26 Number of participants that the trial has enrolled


Contact us.